Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Alzheimer's DiseaseCognitive Impairment
Interventions
DRUG

EGb761®

Four weeks for AD patients, 18 months for MC and CNE patients

DRUG

Placebo

Placebo 1 tablet BID

Trial Locations (8)

75009

Private practice, Paris

75013

Hôpital Broca 54-56 rue Pascal, Paris

Unknown

Hôpital Corentin Celton 4 parvis Corentin Celton, Issy-les-Moulineaux

Hôpital de Juvisy, Juvisy-sur-Orge

"CMPI Les Rives de Seine", Le Vésinet

Centre Hospitalier d'Orsay 4 place du Général Leclerc, Orsay

Observatoire de l'âge, Paris

Hôpital Paul Brousse 12 av Paul-Vaillant-Couturier, Villejuif

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY